17-21 June, Gothenburg
![]() |
![]() |
![]() |
![]() |
1-P | Utilisation of LEAN Startup Methodology for the Identification, Development, and Pilot of Novel Services that can be Provided to Hospital Transfusion Laboratories. | matthew hazell | ![]() |
![]() |
|||
3-P | Characterizing the Transfusion Continuum in a Low-Resource Referral Hospital in Kenya: A Qualitative Study of Emergency Transfusion Measures | Cindy Makanga | ![]() |
![]() |
|||
13-P | ONBOARDING THE WOG WORKFLOW MANAGEMENT SYSTEM FOR A ROBUST OCCURRENCE REPORTING SYSTEM | Thilakavathi J | ![]() |
![]() |
|||
16-P | Evaluation of a new-generation nucleic acid testing (NAT) middleware to improve process efficiency through full real-time monitoring of the NAT instrumentation | Fatima Lopez | ![]() |
![]() |
|||
24-P | Developing Immersive Virtual Reality for Transfusion Laboratory Training | Laura Eastwood | ![]() |
![]() |
|||
25-P | Pilot of an Immersive Virtual Reality Red Blood Cell Crossmatching Training Package | Laura Eastwood | ![]() |
![]() |
|||
31-P | Collaboration & communication: key elements of implementing state-wide change to reduce O RhD negative red blood cell use | Linley Bielby | ![]() |
![]() |
|||
35-P | Plasma self-sufficiency: insights for the success of the action plan | Pilar Córdoba | ![]() |
![]() |
|||
36-P | INCREASING EFFICIENCY AND EFFECTIVENESS BY MODIFYING BLOOD BANK CROSS MATCHING POLICY | Hanna morani | ![]() |
![]() |
|||
42-P | Optimising WB component supply A Monte Carlo simulation model | Josephine McCullagh | ![]() |
![]() |
|||
43-P | Insuring blood supply and financial sustainability with a new university-based blood bank | Marcia Cardoso | ![]() |
![]() |
|||
44-P | 6-month experiences with platelet inventory management by RFID Smart Storage Solution | Nicolas de Valensart | ![]() |
![]() |
|||
46-P | Analysis of appropriate indications and outcomes of patients receiving plasma-reduced platelet transfusions | Hartirathpal Kaur | ![]() |
![]() |
|||
69-P | Changes in demography and infectious disease prevalence in US blood donors during the COVID-19 pandemic on behalf of the US TTIMS Program | Galen Conti | ![]() |
![]() |
|||
71-P | Post Donation Call Back in Singapore: A Review of Cases from 2020-2022 | RAMIR ALCANTARA | ![]() |
![]() |
|||
79-P | Donation drivers and brakes: a qualitative approach to the human condition | Pilar Córdoba | ![]() |
![]() |
|||
80-P | Impact of WhatsApp on donor invitations | Pilar Córdoba | ![]() |
![]() |
|||
81-P | Connecting with donors: empathy maps | Pilar Córdoba | ![]() |
![]() |
|||
87-P | Platelet transfusion to patients with CD36 isoantibody | Brigitte Flesch | ![]() |
![]() |
|||
89-P | Removal of UK-residence deferral for variant Creutzfeldt-Jakob disease: impact on donor sufficiency in Australia | Veronica Hoad | ![]() |
![]() |
|||
93-P | How to Ensure a Memorable Donation Experience | Pilar Córdoba | ![]() |
![]() |
|||
96-P | Influencing first time donors to return. | Simon Davies | ![]() |
![]() |
|||
98-P | Ferritin testing as a risk mitigation strategy to protect frequent whole blood donors at Health Sciences Authority (HSA), Singapore | Wooi Seong Kam | ![]() |
![]() |
|||
102-P | Blood donors profile in a Costa Rican regional hospital from 2015 to 2019 | Wendy Ordóñez Varela | ![]() |
![]() |
|||
115-P | Simulated effects of ferritin screening on hs-CRP in recruited donors | Esa Turkulainen | ![]() |
![]() |
|||
130-P | CD4 lymphopenia among French cytapheresis donors | Pascale Richard | ![]() |
![]() |
|||
138-P | PREDICTING WHO IS AT RISK OF EXPERIENCING VASOVAGAL REACTIONS USING PRE-DONATION ANTICIPATED EMOTIONAL STATES. | Judita Rudokaite | ![]() |
![]() |
|||
149-P | DEHT-PAGGSM blood bag devices do not affect the quality results on the processing Multicentric and collaborative study | Anais Lotens | ![]() |
![]() |
|||
156-P | DONOR FACTORS AFFECTING PLATELET RECOVERY FROM WHOLE BLOOD DONATIONS AND BEST WHOLE BLOOD DONORS FOR PLATELETS | Ana Pérez | ![]() |
![]() |
|||
163-P | Characterization of residual cell populations in leukoreduction system (LRS) disposable sets following apheresis platelet collections in plasma versus PAS | Susanne Marschner | ![]() |
![]() |
|||
165-P | How to minimize residual cells in specific blood components. Optimizing an automated processing system | MARTINEZ NURIA | ![]() |
![]() |
|||
180-P | Evaluation of thawing Fresh Frozen Plasma at 37oC and 45oC | Josephine McCullagh | ![]() |
![]() |
|||
181-P | Qualification of a residual white blood cell counter based on fluorescent microscopy | Anais Lotens | ![]() |
![]() |
|||
182-P | EBA Working Group, European Quality Control Proficiency Testing Scheme | Nadine Marpaux | ![]() |
![]() |
|||
183-P | Comparison between fluorescent microscopy and cytometry for residual white blood cell counting in blood components | Anais Lotens | ![]() |
![]() |
|||
191-P | Patient reported outcomes of Serum Eye Drops (SED) manufactured from Australian blood donations and packaged using MEISE vials | Phillip Mondy | ![]() |
![]() |
|||
205-P | INITIAL EXPERIENCE OF SWITCHING PATHOGEN INACTIVATION SYSTEM WITH EXTENDED PLATELET SHELF LIFE | Nicolas Malvaux | ![]() |
![]() |
|||
207-P | PATHOGEN REDUCED PLASMAS FROM MAXI-POOLS COMBINED WITH FAST THAWING FOR USE IN EMERGENCY SITUATIONS | Marja-Kaisa Auvinen | ![]() |
![]() |
|||
217-P | Granulocyte pooling: an alternative to the classical collection method from apheresis? | MARTINEZ NURIA | ![]() |
![]() |
|||
224-P | Prevalence of acute Hepatitis E virus infections in Swiss Blood Donations 2018-2020 | Peter Gowland | ![]() |
![]() |
|||
225-P | 21 years experience in NAT screening of blood donors: analyisis of data recorded at ASST-Spedali Civili, Brescia (Italy) | Susanna Bresciani | ![]() |
![]() |
|||
228-P | Global Nucleic Acid Amplification Testing (NAT) Use and Confirmatory Testing Approaches in Blood Donor Screening | Helen Faddy | ![]() |
![]() |
|||
230-P | Seroprevalence of transfusion-transmissible infections among blood donors in Nigeria: a retrospective analysis of blood donor data in the six geo-political regions. | Adaeze Oreh | ![]() |
![]() |
|||
231-P | Comparison of two automated NAT systems for HIV, HBV, and HCV | Jean Stanley | ![]() |
![]() |
|||
235-P | Improved efficiency using sequential screening assays for Treponema pallidum (syphilis) in blood donations | Anthea Cheng | ![]() |
![]() |
|||
254-P | Risk factors of hepatitis C infection in Repeated Donors Vary Geographically: A nested case-control study | Ching-Mei Yu | ![]() |
![]() |
|||
257-P | Evaluation of HIV immunoassays for blood donor screening using nationwide real-world data | Guillermo Andres Orjuela-Falla | ![]() |
![]() |
|||
263-P | Comparable detection of bacterial contamination in apheresis platelet concentrates suspended in plasma or platelet additive solution E with an automated culture method | Sandra Ramirez-Arcos | ![]() |
![]() |
|||
265-P | DETECTION OF PLASMODIUM IN SPECIMENS FROM HEALTHY ASYMPTOMATIC INDIVIDUALS IN NIGERIA BY COBAS MALARIA | XIAOMEI ZHU | ![]() |
![]() |
|||
269-P | Anti-SARS-CoV-2 antibody development during the COVID-19 pandemic in Swiss blood donors | Peter Gowland | ![]() |
![]() |
|||
274-P | Development of a Mayaro and Yellow fever virus duplex real-time RT-PCR assay for high-throughput testing | Carlo Fischer | ![]() |
![]() |
|||
282-P | TRANSMISSION OF VARIANT CREUTZFELDT-JAKOB DISEASE THROUGH BLOOD TRANSFUSION AND PLASMA-DERIVED PRODUCTS: A NARRATIVE REVIEW OF OBSERVED AND MODELIZED RISKS | Lewin Antoine | ![]() |
![]() |
|||
284-P | Evaluation of a novel monoclonal anti-Vel phenotyping reagent. | Gareth Nottage | ![]() |
![]() |
|||
287-P | IMPLEMENTATION OF ERYTRA AUTOMATED ANALYSER FOR BLOOD GROUP TYPING IN A BLOOD DONOR SETTING: EXPERIENCE AND FIRST RESULTS | Caroline Tinguely | ![]() |
![]() |
|||
288-P | An Improved Approach to Detecting the Variant RhD - DVI in Donors | Tony Casina | ![]() |
![]() |
|||
300-P | Paroxysmal cold hemoglobinuria in a pediatric patient with concurrent warm and cold autoantibodies | Keenan Hogan | ![]() |
![]() |
|||
315-P | MULTIDISCIPLINAR MANAGEMENT AND OUTCOME OF A PREGNANT WOMEN WITH H DEFICIENT RED CELLS (BOMBAY PHENOTYPE) | Angel Luis Pajares Herraiz | ![]() |
![]() |
|||
316-P | Five Cases of Piperacillin-Induced Immune Haemolytic Anaemia | Claudia Ruhland | ![]() |
![]() |
|||
328-P | IMPLEMENTATION OF AUTOMATED SEROLOGICAL CROSSMATCH PROCESS FOR PRBC TRANSFUSION IN A HOSPITAL BLOOD TRANSFUSION SERVICE | Niythiya Mohan | ![]() |
![]() |
|||
331-P | Performance evaluation of a new Direct Coombs card based on column agglutination system | Laziza Amniai | ![]() |
![]() |
|||
338-P | CEPHALOSPORINS INDUCED HEMOLYTIC ANEMIA: A CASE STUDY | Graa Almeida | ![]() |
![]() |
|||
347-P | Identifying RHCE variants in Flanders (Belgium) and implications on regional transfusion policy | Vicky Van Sandt | ![]() |
![]() |
|||
351-P | BLOOD GROUP GENOTYPING IN DONORS OF AFRICAN DESCENT | Rahel Kräuchi | ![]() |
![]() |
|||
355-P | A NOVEL RHD ALLELE IN A CAUCASIAN BLOOD DONOR | Laziza Amniai | ![]() |
![]() |
|||
356-P | Characterization of three novel RHCE mutations inducing aberrant C expression | Sarah Petermann | ![]() |
![]() |
|||
366-P | A novel missense variant c.1AT on the ABO*B.01 allele associated with a Bw phenotype | Ji Yeong Seo | ![]() |
![]() |
|||
367-P | A novel frameshift mutation in the XK gene in a Finnish patient with McLeod syndrome | Susanna Sainio | ![]() |
![]() |
|||
369-P | Diagnosis of variant D phenotype (DIII type 7) in a patient with anti-D alloantibody | Ignacio Pereira | ![]() |
![]() |
|||
370-P | Two novel alleles harboring a deletion in the KEL and RH blood group system | Christine Henny | ![]() |
![]() |
|||
402-P | A National Comparison of the Uncertainty of Measurement in different D Positive Red Cell Volumes by Flow Cytometry | Vera Rosa | ![]() |
![]() |
|||
406-P | ANTI-U IN PREGNANCY AND HAEMOLYTIC DISEASE OF THE FETUS AND NEWBORN: A CASE SERIES AND LITERATURE REVIEW | Harshita Rajasekariah | ![]() |
![]() |
|||
409-P | Follow-up with titration in pregnancy for suspected allo-anti-HPA5b FNAIT: case study | Susanna Bresciani | ![]() |
![]() |
|||
445-P | Rethinking and personalising the transfusion pathway in myelodysplastic syndromes (MDS): a novel trial of weekly matched red cell transfusion to improve quality of life | Allison Mo | ![]() |
![]() |
|||
446-P | Does treatment of anaemia improve quality of life or physical function for patients with myelodysplastic syndromes (MDS): a systematic review | Allison Mo | ![]() |
![]() |
|||
462-P | Platelet transfusion and Rh-D alloimmunization, is prophylaxis still required? | Nour AlMozain | ![]() |
![]() |
|||
471-P | Development of an immunodeficient mouse model of massive haemorrhage with acute thrombocytopaenia to validate the haemostatic effect of human platelet transfusion | Keita Uchiyama | ![]() |
![]() |
|||
472-P | AN APPROACH TO EMERGENCY TRANSFUSION IN TRAUMA AND HAEMORRHAGE: ANALYSIS OF URGENT BLOOD SUPPLY CASES IN SLIM RIVER HOSPITAL, MALAYSIA | Irni MOHD YASIN | ![]() |
![]() |
|||
479-P | Evaluation of Clinical Outcomes and Healthcare Resource Utilization in Patients with Sickle Cell Disease Before and After Suspected Alloimmunization: Real-world Evidence from 2011 to 2021 | CRISTINA COLL-ORTEGA | ![]() |
![]() |
|||
490-P | Factors Associated with Mortality in Transfusion Associated Circulatory Overload | Mark John McVey | ![]() |
![]() |
|||
511-P | Screening for Iron Deficiency among Pregnant Women | Wejdan AlQurashi | ![]() |
![]() |
|||
519-P | Autologous Tansfusion REquirements in bone MArrow harvest: preliminary results of the ATREMA study. | Luciana Teofili | ![]() |
![]() |
|||
537-P | Reducing the DMSO concentration in the cryopreservation mixture from 10 to 5 improves cell viability, results of a validation study. | Nour AlMozain | ![]() |
![]() |
|||
542-P | Determination of genetic markers of alloimmunization: Association between the presence of alloantibodies against erythrocyte antigens and specific HLA class II alleles. | María Antonieta Nuñez | ![]() |
![]() |
17-21 June, Gothenburg
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|